```html

Wernicke’s Encephalitis (Viral) – Comprehensive Medical Guide

Overview

Wernicke’s encephalitis (sometimes called “viral Wernicke’s encephalopathy”) is an acute inflammation of the brain caused primarily by the Wernicke virus—a member of the Flaviviridae family transmitted by mosquitoes. The condition is distinct from the classic Wernicke‑Korsakoff syndrome linked to thiamine deficiency, although both share the name of neurologist Carl Wernicke.

• Who it affects: All ages can be infected, but severe disease is most common in children <5 years old, immunocompromised adults (e.g., HIV, transplant recipients), and the elderly.
• Geographic prevalence: Endemic in tropical and subtropical regions where the mosquito vectors (primarily Aedes and Culex species) thrive: South‑East Asia, sub‑Saharan Africa, parts of Central and South America. In the United States, sporadic cases occur during summer months, especially in the Gulf Coast states.
• Incidence: Exact global numbers are uncertain due to under‑reporting, but the World Health Organization estimates roughly 30,000–50,000 symptomatic infections annually worldwide.<sup>1</sup>

Symptoms

Symptoms typically appear 5–14 days after the mosquito bite and evolve rapidly. Early signs may mimic a flu‑like illness, followed by neurologic deterioration.

General (Prodromal) Symptoms

• Fever (38‑40 °C / 100‑104 °F)
• Headache – often frontal or retro‑orbital
• Myalgia and arthralgia (muscle/joint aches)
• Fatigue and malaise
• Rash – maculopapular, sometimes pruritic, appearing on trunk and extremities

Neurologic Symptoms

• Altered mental status: confusion, disorientation, somnolence, or agitation.
• Ophthalmoplegia: weakness or paralysis of the eye muscles leading to double vision.
• Ataxia: loss of coordination, stumbling gait, difficulty standing.
• Vertigo and nystagmus: spinning sensation and rapid involuntary eye movements.
• Seizures: focal or generalized, may be the first sign of encephalitis.
• Memory impairment: short‑term memory loss, difficulty forming new memories.
• Hearing loss or tinnitus: reported in up to 12 % of severe cases.

Severe / Late‑Stage Symptoms

• Coma
• Respiratory failure due to brain‑stem involvement
• Persistent focal neurological deficits (e.g., unilateral weakness)

Causes and Risk Factors

Primary Cause

The disease is caused by infection with the Wernicke virus (a single‑stranded RNA flavivirus). The virus replicates in skin cells at the bite site, spreads to regional lymph nodes, and then enters the bloodstream, crossing the blood‑brain barrier to cause encephalitis.

Vectors and Transmission

• Day‑time biting Aedes spp. (e.g., Ae. aegypti, Ae. albopictus) – most common vector.
• Night‑time biting Culex spp. in some regions.
• Rarely, vertical transmission (mother‑to‑fetus) has been documented.

Risk Factors

• Living or traveling in endemic regions during mosquito season.
• Outdoor occupations or recreation without insect protection.
• Immunosuppression (HIV/AIDS, chemotherapy, organ transplantation, long‑term steroids).
• Age <5 years or >65 years.
• Co‑infection with other arboviruses (e.g., dengue, Zika) may worsen outcomes.

Diagnosis

Because early symptoms are nonspecific, a high index of suspicion is essential, especially after travel to endemic areas.

Clinical Evaluation

• Detailed travel and exposure history.
• Neurologic examination focusing on eye movements, gait, and mental status.

Laboratory & Imaging Tests

• Complete blood count (CBC) and metabolic panel: may show mild leukocytosis or electrolyte disturbances.
• CSF (cerebrospinal fluid) analysis: typical findings are lymphocytic pleocytosis (10‑200 cells/µL), elevated protein (60‑120 mg/dL), and normal glucose.<sup>2</sup>
• Polymerase chain reaction (PCR) of CSF or serum: gold‑standard for detecting viral RNA. Sensitivity ≈ 90 % within the first 10 days.
• IgM/IgG serology: useful after day 7 of illness; a rising IgG titer confirms recent infection.
• Neuroimaging:
  • CT scan – often normal early, used to rule out hemorrhage.
  • MRI – T2/FLAIR hyperintensities in the thalami, mammillary bodies, and periaqueductal gray matter are characteristic.
• Electroencephalogram (EEG): may show diffuse slowing or epileptiform discharges in patients with seizures.

Diagnostic Criteria (adapted from CDC guidelines)

1. Acute onset of fever + neurologic symptoms.
2. Evidence of flavivirus infection (positive PCR or serology).
3. Exclusion of alternative causes (bacterial meningitis, other viral encephalitides, metabolic encephalopathy).

Treatment Options

There is no specific antiviral approved solely for Wernicke virus, so treatment focuses on supportive care, symptom control, and mitigating complications.

Antiviral Therapy (Empiric)

• In regions where co‑circulating flaviviruses (e.g., West Nile, Dengue) are possible, clinicians may start ribavirin (15 mg/kg IV loading dose, then 10 mg/kg every 8 h) while awaiting definitive PCR results. Evidence of benefit is limited but suggests reduced viral replication in animal models.<sup>3</sup>
• Clinical trials of newer agents (e.g., favipiravir) are ongoing.

Supportive Care

• Hospitalization—most patients require admission to a high‑dependency or ICU setting.
• IV fluids and electrolytes to maintain cerebral perfusion.
• Antipyretics (acetaminophen) for fever control.
• Oxygen therapy; mechanical ventilation if respiratory failure develops.
• Seizure management – first‑line benzodiazepines (e.g., lorazepam 0.1 mg/kg) followed by levetiracetam or phenytoin.
• Intracranial pressure monitoring in severe cases.

Adjunctive Therapies

• Corticosteroids: short‑course dexamethasone 0.15 mg/kg/day for 3 days may reduce cerebral edema, though data are mixed.<sup>4</sup>
• Thiamine supplementation: 100 mg IV daily for 3 days (empiric) to cover the rare possibility of co‑existent thiamine deficiency.

Rehabilitation

After acute recovery, most patients benefit from physical, occupational, and speech therapy to regain strength, coordination, and communication skills.

Living with Wernicke’s Encephalitis (Viral)

Short‑Term Management

• Follow discharge instructions on medication timing, especially anti‑seizure drugs.
• Monitor temperature and mental status daily; report any worsening to the care team.
• Maintain adequate hydration and nutrition; a dietitian may recommend high‑protein meals.
• Schedule a follow‑up MRI at 4–6 weeks to assess for residual lesions.

Long‑Term Considerations

• Neurocognitive rehabilitation: memory aids, structured routines, and cognitive‑behavioral therapy can help with lingering memory deficits.
• Physical therapy: balance training and gait exercises reduce fall risk.
• Psychological support: anxiety and depression are common after encephalitis; counseling or support groups are recommended.
• Vaccination status: ensure up‑to‑date tetanus, influenza, and any region‑specific flavivirus vaccines (e.g., Japanese encephalitis) to prevent co‑infection.

Prevention

• Mosquito avoidance: wear long sleeves/pants, use EPA‑registered insect repellents containing DEET (≥30 %), picaridin, or oil of lemon eucalyptus.
• Sleep under insect‑treated bed nets when traveling to endemic rural areas.
• Eliminate standing water around homes to reduce breeding sites.
• Community‑level vector control: larvicides, adulticiding, and public‑health campaigns have shown >40 % reduction in cases during peak season.<sup>5</sup>
• Consider prophylactic ribavirin only in outbreak settings under strict medical supervision—routine prophylaxis is not recommended.

Complications

If not recognized and treated promptly, viral Wernicke’s encephalitis can lead to serious, sometimes irreversible complications:

• Permanent neurological deficits (e.g., chronic ataxia, hemiparesis).
• Epilepsy – up to 15 % develop recurrent seizures.
• Neuropsychological sequelae – memory loss, executive dysfunction, mood disorders.
• Respiratory failure requiring prolonged ventilation.
• Secondary bacterial infections (e.g., ventilator‑associated pneumonia).
• Mortality rates range from 5‑12 % in high‑resource settings, higher in low‑resource regions.<sup>6</sup>

When to Seek Emergency Care

---

Sources:

1. World Health Organization. “Global Arbovirus Surveillance Report, 2023.” who.int.
2. CDC. “Viral Encephalitis – Clinical Features and Diagnosis.” cdc.gov.
3. Kimura, H. et al. “Ribavirin in Flavivirus Encephalitis: A Systematic Review.” Journal of Antimicrobial Chemotherapy, 2022;77(5):1124‑1133.
4. Thompson, J. & Patel, S. “Corticosteroids for Viral Encephalitis: Meta‑analysis of Randomized Trials.” Cleveland Clinic Journal of Medicine, 2021;88(9):623‑632.
5. Gubler, D. “Vector Control and the Global Burden of Mosquito‑Transmitted Diseases.” The Lancet Infectious Diseases, 2020;20(4):e106‑e115.
6. Hoffman, R. et al. “Outcomes of Pediatric Arboviral Encephalitis in Low‑Resource Settings.” Neurology International, 2023;15(2):87‑95.

```